T cells are a type of immune cell involved in identifying and killing cancer cells. T cells that infiltrate tumors, known as tumor infiltrating T cells (TILs), are a positive prognostic factor for cancer patients. Cellular therapies remove TILs from a patient, expand them in a laboratory, and administer them back to the patient.
B cell responses within pancreatic ductal adenocarcinoma (PDAC) tumors are associated with improved patient outcomes, yet the specific triggering antigens remain largely unknown. In this web...
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...
Date: December 07, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Join us for an exciting live panel webinar, as we celebrate the 60th anniversary of Gibco Cell Culture. The panelists...
Date: November 4, 2021 Time: 8:00am (PDT), 11:00am (EDT) The promise of tissue clearing techniques in combination with 3D-immunofluorescence (IF) microscopy is revolutionary. Complex biologi...
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
Date: August 26, 2021 Time: 7:00am (PDT), 10:00am (EDT) Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with rising incidence and a remarkable resistance to current therapies. In t...
T-cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor-infiltrating lymphocytes and peripheral...
Hypoxia is pervasive across human cancer and its association with poor outcomes and aggressive malignant phenotypes has been increasingly appreciated. Previously, we and others described how...
Despite the promising results with current approved immunotherapies, all patients do not have the same level of response, and recent efforts have focused on understanding and avoiding immuno...
Learning Objectives: 1. Define the impact of PD-L1 expressed on non-tumor, non-hematopoietic cells in T cell-mediated tumor control 2. Reveal the contribution of IFNg signaling in dermal lym...
Progress developing immune-based treatments to treat the highly lethal pancreatic ductal adenocarcinoma (PDA) has lagged behind other cancer types. This may be due, in part, to a fibroinflam...
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
DATE: April 08, 2021 TIME: 08:00am PDT Multi-omics involves the use of different data modalities to study multiple “omes”, such as the genome, transcriptome, epigenome, and/or t...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
DATE: September 1, 2020 TIME: 8:00am PT, 11:00am ET Nearly half of all cancer patients are eligible to receive treatment with immune checkpoint inhibitors (ICI). Thus, preventing, identifyin...
Metabolic reprogramming is critical for governing proper T cell immune responses, including activation, production of effector molecule, migration and differentiation. The metabolic stress T...
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
1. Identify 3 barriers to immune cell response to cancer 2. List 3 approaches to overcome immunosuppressive barriers to bolster the immune response to cancer 3. Explain how fusion proteins c...
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify patient-responders from non-re...
B cell responses within pancreatic ductal adenocarcinoma (PDAC) tumors are associated with improved patient outcomes, yet the specific triggering antigens remain largely unknown. In this web...
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...
Date: December 07, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Join us for an exciting live panel webinar, as we celebrate the 60th anniversary of Gibco Cell Culture. The panelists...
Date: November 4, 2021 Time: 8:00am (PDT), 11:00am (EDT) The promise of tissue clearing techniques in combination with 3D-immunofluorescence (IF) microscopy is revolutionary. Complex biologi...
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
Date: August 26, 2021 Time: 7:00am (PDT), 10:00am (EDT) Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with rising incidence and a remarkable resistance to current therapies. In t...
T-cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor-infiltrating lymphocytes and peripheral...
Hypoxia is pervasive across human cancer and its association with poor outcomes and aggressive malignant phenotypes has been increasingly appreciated. Previously, we and others described how...
Despite the promising results with current approved immunotherapies, all patients do not have the same level of response, and recent efforts have focused on understanding and avoiding immuno...
Learning Objectives: 1. Define the impact of PD-L1 expressed on non-tumor, non-hematopoietic cells in T cell-mediated tumor control 2. Reveal the contribution of IFNg signaling in dermal lym...
Progress developing immune-based treatments to treat the highly lethal pancreatic ductal adenocarcinoma (PDA) has lagged behind other cancer types. This may be due, in part, to a fibroinflam...
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
DATE: April 08, 2021 TIME: 08:00am PDT Multi-omics involves the use of different data modalities to study multiple “omes”, such as the genome, transcriptome, epigenome, and/or t...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
DATE: September 1, 2020 TIME: 8:00am PT, 11:00am ET Nearly half of all cancer patients are eligible to receive treatment with immune checkpoint inhibitors (ICI). Thus, preventing, identifyin...
Metabolic reprogramming is critical for governing proper T cell immune responses, including activation, production of effector molecule, migration and differentiation. The metabolic stress T...
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
1. Identify 3 barriers to immune cell response to cancer 2. List 3 approaches to overcome immunosuppressive barriers to bolster the immune response to cancer 3. Explain how fusion proteins c...
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify patient-responders from non-re...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
